- Home
- NBP vs AVTX Comparison
NBP vs AVTX Comparison
Compare NBP & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.2M | 328.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBP | AVTX |
|---|---|---|
| Price | $1.77 | $16.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $40.57 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.67 | $3.43 |
| 52 Week High | $5.19 | $24.27 |
Technical Indicators
Market Signals| Indicator | NBP | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.14 | 47.87 |
| Support Level | N/A | $13.70 |
| Resistance Level | $2.73 | $19.39 |
| Average True Range (ATR) | 0.12 | 1.98 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 10.67 | 23.65 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.